Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation

The purpose of this study is to evaluate changes in adrenal hormones during adrenal radiofrequency (RF) ablation.

Lead sponsor: Mie University•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

Active Not RecruitingPhase 2/3

11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours

NCT06100367 · Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism, and more

COMPLETEDPhase 1

Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)

NCT00591643 · Adrenal Tumors, Adrenal Malignancies, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 28, 2015Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2/PHASE3

Enrollment18

Start dateOct 2009

Last updatedApr 28, 2015

Condition

Adrenal Tumors

Locations shown

Mie University Hospital

Tsu, Mie-ken

Mie University

Tsu, Mie-ken

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 28, 2015Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions